Bioequivalence Study of Zolpidem Tartrate Tablets and Ambien® Under Fasting Conditions

This study has been completed.
Sponsor:
Information provided by:
Mutual Pharmaceutical Company, Inc.
ClinicalTrials.gov Identifier:
NCT00684814
First received: May 24, 2008
Last updated: April 18, 2012
Last verified: April 2012
  Purpose

The purpose of this study is to compare the bioequivalence of a test formulation of zolpidem tartrate tablets to an equivalent oral dose of the commercially available reference drug product Ambien® (zolpidem tartrate tablets) in adult subjects under fasted conditions.


Condition Intervention Phase
Healthy
Drug: Zolpidem Tartrate 10 mg tablet
Drug: Zolpidem Tartrate 10 mg tablet (Ambien®)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: A Randomized, Two-way Crossover, Single-Dose, Open-Label Study to Evaluate the Relative Bioequivalence of a Test Tablet Formulation of Zolpidem Tartrate 10 mg, Compared to an Equivalent Dose of Ambien® in Healthy Adult Subjects.

Resource links provided by NLM:


Further study details as provided by Mutual Pharmaceutical Company, Inc.:

Primary Outcome Measures:
  • Maximum Plasma Concentration (Cmax) for Zolpidem Tartrate [ Time Frame: serial pharmacokinetic blood samples drawn prior to dosing (hour 0), and then at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 4, 5, 6, 8, 10, and 12 hours after dose administration ] [ Designated as safety issue: No ]
    The maximum or peak concentration that zolpidem tartrate reaches in the plasma.

  • Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Zolpidem Tartrate [ Time Frame: serial pharmacokinetic blood samples drawn prior to dosing (hour 0), and then at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 4, 5, 6, 8, 10, and 12 hours after dose administration ] [ Designated as safety issue: No ]
    The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable zolpidem tartrate concentration (t), as calculated by the linear trapezoidal rule.

  • Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]for Zolpidem Tartrate [ Time Frame: serial pharmacokinetic blood samples drawn prior to dosing (hour 0), then 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 4, 5, 6, 8, 10, and 12 hours after dose administration ] [ Designated as safety issue: No ]
    The area under the zolpidem tartrate plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.


Enrollment: 38
Study Start Date: May 2004
Study Completion Date: May 2004
Primary Completion Date: May 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Zolpidem Tartrate 10 mg Tablets
A single dose of zolpidem tartrate 10 mg administered after an overnight fast of at least 10 hours.
Drug: Zolpidem Tartrate 10 mg tablet
10 mg tablet administered after an overnight fast of at least 10 hours
Experimental: Zolpidem Tartrate (Ambien®) 10 mg Tablets
A single dose of Ambien® 10 mg administered after an overnight fast of at least 10 hours.
Drug: Zolpidem Tartrate 10 mg tablet (Ambien®)
10 mg tablet administered after an overnight fast of at least 10 hours
Other Name: Ambien®, Sanofi-Synthelabo Inc.

Detailed Description:

The purpose of this study is to compare the bioequivalence of a test formulation of zolpidem tartrate tablets to an equivalent oral dose of the commercially available reference drug product Ambien® (zolpidem tartrate tablets) in adult subjects under fasted conditions.

Thirty-eight healthy, non-smoking, non-obese male and female volunteers at least 18 years of age will be randomly assigned in a crossover fashion to receive each of two zolpidem tartrate dosing regimens in sequence with a 7 day washout period between dosing periods. On the morning of Day 1, after an overnight fast of at least 10 hours, subjects will receive either a single oral dose of the test formulation, zolpidem tartrate (1 x 10 mg tablet) or a single oral dose of the reference formulation, Ambien® (1 x 10 mg tablet). After a 7 day washout period, on the morning of Day 8 after an overnight fast, subjects will receive the alternate regimen. Blood samples will be drawn from all participants before dosing and for 12 hours post dose at times sufficient to adequately define the pharmacokinetics of zolpidem tartrate. A further goal of this study is to evaluate the safety and tolerability of this regimen in healthy volunteers. Subjects will be monitored throughout the confinement portion of the study for adverse reactions to the study drugs and/or procedures. Blood pressure and pulse rate will be obtained prior to dosing and at 0.5, 1, 2, 4 and 12 hours post-dose. All adverse events whether elicited by query, spontaneously reported or observed by clinic staff will be evaluated by the investigator and reported in the subject's case report form.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Sex: Male or Female; similar proportions of each preferred
  • Age: At least 18 years
  • Weight: must be 15% of ideal weight for height and frame
  • Subjects must be in good health and physical condition as determined by medical history
  • Subjects must read and sign the Consent Form

Exclusion Criteria:

  • History of treatment for alcoholism, substance abuse, or drug abuse within past 24 months.
  • History of malignancy, stroke, diabetes, cardiac, renal or liver disease, or other serious illness.
  • History of GERD, malabsorption syndrome, colon cancer, or chronic colitis, including Crohn's disease.
  • History of treatment for asthma within the past five (5) years.
  • History of mental depression.
  • History of pulmonary disease.
  • History of sleep apnea.
  • Females who are pregnant or lactating.
  • History of hypersensitivity to zolpidem tartrate, or any hypnotic or sedative.
  • Treatment with any other investigational drug during the four weeks prior to the initial dosing of the study.
  • Donation of blood within four weeks prior to the initial dosing of the study
  • Smokers or subjects who use tobacco/nicotine products. Three months abstinence is required.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Additional Information:
No publications provided

Responsible Party: Vice President R&D, Mutual Pharmaceutical Company, Inc.
ClinicalTrials.gov Identifier: NCT00684814     History of Changes
Other Study ID Numbers: 04064
Study First Received: May 24, 2008
Results First Received: December 4, 2009
Last Updated: April 18, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Mutual Pharmaceutical Company, Inc.:
equivalency
Therapeutic equivalency

Additional relevant MeSH terms:
Zolpidem
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 28, 2014